This company has been marked as potentially delisted and may not be actively trading. NYSE:TMBR Timber Pharmaceuticals (TMBR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Timber Pharmaceuticals Stock (NYSE:TMBR) 30 days 90 days 365 days Advanced Chart Get Timber Pharmaceuticals alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.34▼$2.9452-Week Range N/AVolume26,307 shsAverage Volume511,937 shsMarket Capitalization$1.21 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. The company was founded in 2019 and is headquartered in Warren, New Jersey. Read More Receive TMBR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Timber Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address TMBR Stock News HeadlinesMSG Networks in talks to avoid bankruptcy — possibly with help of Amazon: sourcesJanuary 31, 2025 | nypost.comNTimber back in Dutch squad and twin brother also called upAugust 30, 2024 | reuters.com“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.August 26 at 2:00 AM | InvestorPlace (Ad)Can timber construction overcome its growing pains?May 13, 2024 | reuters.comTimber Pharmaceuticals, Inc., a LEO Pharma Company, Presents Late-Breaking Preliminary Results of TMB-001 in Moderate-to-Severe Congenital Ichthyosis (CI) at the 2024 AAD Annual MeetingMarch 10, 2024 | businesswire.comTimber Pharmaceuticals Announces Official Name ChangeJanuary 28, 2024 | msn.comTimber Pharmaceuticals Inc (TMBRQ)January 13, 2024 | uk.investing.comTimber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC MarketNovember 29, 2023 | finance.yahoo.comSee More Headlines TMBR Stock Analysis - Frequently Asked Questions When did Timber Pharmaceuticals' stock split? Timber Pharmaceuticals shares reverse split before market open on Wednesday, November 9th 2022.The 1-50 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. What other stocks do shareholders of Timber Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Timber Pharmaceuticals investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), Castor Maritime (CTRM) and Phunware (PHUN). Company Calendar Today8/26/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:TMBR CIK1504167 Webwww.timberpharma.com Phone(973) 314-9577FaxN/AEmployees9Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$19.38 million Net MarginsN/A Pretax MarginN/A Return on Equity-511.45% Return on Assets-180.93% Debt Debt-to-Equity RatioN/A Current Ratio0.50 Quick Ratio0.50 Sales & Book Value Annual Sales$80 thousand Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.79 per share Price / BookN/AMiscellaneous Outstanding Shares3,430,000Free Float3,378,000Market Cap$1.21 million OptionableNot Optionable Beta0.03 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NYSE:TMBR) was last updated on 8/26/2025 by MarketBeat.com Staff From Our Partners$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredHow 8,000+ investors trade crypto with a 93% win rateThere are 18,347 cryptocurrencies in the market right now. 99% of them will fail. And trying to pick winner...Crypto Swap Profits | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Timber Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Timber Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.